MarketBeat
12 Jul 2026, 22:02 UTC · 2h ago
Teva Pharmaceutical Industries' Anti-IL-15 Antibody Shows Promise in Vitiligo Study
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
12 Jul 2026, 22:02 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Teva expects its innovative portfolio to generate $3.5 billion in revenue by 2026. — Providing a concrete, multi-billion dollar revenue target for its pivot to biopharma offers a clear valuation metric for investors.
+0.60Teva's anti-IL-15 antibody showed encouraging phase 1b efficacy results for vitiligo, with a potential for once-quarterly dosing. — Positive early-stage data and a significant dosing advantage over daily oral competitors increase the asset's commercial viability.
+0.40Teva identifies six specific pipeline programs, including anti-IL-15 and duvakitug, that it believes could each become $1 billion products. — The claim of multiple potential 'blockbusters' suggests high upside potential for the long-term growth strategy.
+0.30Continue reading
6 related stories
Top 2 movers · tap to explore
Teva expects eight key clinical or regulatory events in 2026, including an ecopipam NDA filing. — An increase in near-term catalysts typically increases stock volatility and provides more opportunities for positive re-ratings.
+0.20Proof-of-concept data from a phase 2a celiac disease study using anti-IL-15 is expected in the second half of the year. — Expansion into additional indications increases the total addressable market for the antibody platform.
+0.10Which stocks this story touches
Positive phase 1b results for vitiligo treatment and a strong pipeline projection for 2026 growth.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
3h ago
